Gates, others launch $654m maternal, newborn health fund, bucking aid cuts trend, World News
LONDON — A group of philanthropies including the Gates Foundation has set up a fund backed with nearly US$500 million (S$654 million) to help save the lives of newborn babies and mothers in sub-Saharan Africa, standing out against a bleak global health funding landscape.
The Beginnings Fund was launched on Tuesday in Abu Dhabi, the home of another key backer — the United Arab Emirates' recently established Mohamed Bin Zayed Foundation for Humanity.
The project has been in the works for at least a year. But its role has become more important as governments worldwide follow the US in pulling back from international aid, its chief executive Alice Kang'ethe told Reuters in an interview.
"It is an opportune moment," she said earlier this month, stressing that the fund aimed to work alongside African governments, experts and organisations rather than parachuting in experts or technologies, an approach she said differed from many traditional donor programmes.
"Two generations ago... women in the UAE used to die during childbirth. More than half of children did not survive past childhood," said Tala Al Ramahi at the Mohamed Bin Fayed Foundation, saying the lessons learnt in what worked to change those outcomes would help inform the effort.
The Beginnings Fund aims to save the lives of 300,000 mothers and newborn babies by 2030, and expand quality care for 34 million mothers and babies.
The partners also pledged US$100 million in direct investments in maternal and child health, separate to the fund.
It plans to operate in Ethiopia, Ghana, Kenya, Malawi, Lesotho, Nigeria, Rwanda, Tanzania, Uganda, and Zimbabwe, focusing on low-cost interventions and personnel in high-burden hospitals. The work will track and target the key reasons babies and mothers die, including infection, severe bleeding for mothers, and respiratory distress for infants.
The world has made major progress in reducing newborn and maternal deaths, halving the neonatal mortality rate between 1990 and 2022. But that progress has stagnated or even reversed in nearly all regions in the last few years, according to the World Health Organisation, which has warned that aid cuts could make this worse.
"Mothers and newborns should not be dying from causes we know how to prevent," said Dr Mekdes Daba, minister of health for Ethiopia, stressing that the majority of deaths are avoidable.
Kang'ethe said the Beginnings Fund, like other philanthropies, was getting calls to fill gaps in global aid funding, but remained focused on its long-term aim of changing the trajectory of mother and newborn survival.
The fund is also backed by the Children's Investment Fund Foundation, Delta Philanthropies and the ELMA Foundation, among others. It will be led from Nairobi, Kenya.
[[nid:716877]]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Straits Times
12 hours ago
- Straits Times
First China weight loss drug emerges
Obesity drugmakers Novo Nordisk and Eli Lilly & Co. now face their first serious rival in China. PHOTO: REUTERS Hong Kong – Novo Nordisk and Eli Lilly & Co, the pharmaceutical giants dominating the global obesity drug market, now face their first serious rival in China. Suzhou-based Innovent Biologics secured approval last week for its treatment mazdutide, a turning point in China's efforts to combat rising obesity and diabetes rates with local innovation. With over 600 million Chinese adults projected to be overweight by 2050, the emergence of a viable local alternative to Novo and Lilly's blockbuster GLP-1 treatments could make weight loss drugs more accessible in the world's second-largest economy. China's nascent weight loss drug market is poised for rapid growth, with analysts estimating it could grow to between US$5.6 billion (S$7.2 billion) and US$11.4 billion a year. While China still accounts for just a fraction of the projected US$150 billion global pie, a raft of homegrown treatments and cheaper generics could significantly improve the availability – and affordability – of the medication. The country has a pipeline of more than 30 late-stage obesity drug candidates under development, according to LEK Consulting. Several firms have already licensed their drugs to US or European drugmakers like AstraZeneca and Merck & Co for further clinical development outside the country. Local biotech firms are promising to overcome the limitations of current treatments, including creating long-awaited GLP-1 pills that are just as effective and safe as weekly injections peddled by Novo and Lilly. Leading insulin producer Gan & Lee Pharmaceutical is pushing ahead a longer-acting drug that can be taken every two weeks, instead of weekly. Laekna is developing a treatment that would help patients preserve more muscle – a common concern among GLP-1 takers – while still losing fat. Hangzhou Sciwind Biosciences expects China will approve its drug ecnoglutide, which led to more than 15 per cent weight loss after 48 weeks when given at the highest dose, in early 2026. 'Multiple Chinese biopharma are developing differentiated and competitive candidates and have the potential to lead the direction of weight loss drug research and development,' said Chen Chen, head of China healthcare research at UBS Securities. Competition is expected to ramp up next year when cheaper alternative versions of semaglutide – the active ingredient in Novo's Wegovy – launch after semaglutide's China patent expires. Their emergence could pressure drugmakers to lower their treatment prices, and could quickly expand access to the drugs across a country of 1.4 billion people. Compared to Western countries where popular GLP-1 drugs are widely available for people looking to lose weight, the current penetration rate for such drugs in China is 'extremely low,' said UBS's Mr Chen. Novo only started rolling out obesity treatments in China in 2024, and Lilly earlier this year. A government-led campaign to curb obesity and establish new weight management clinics has fuelled demand, which is now outstripping supply and leading to stock shortages, said Shawn Qu, chief of SinoUnited Health's Endocrinology, Metabolism and Thyroid Center in Shanghai. 'It's far from meeting the clinical need,' said Mr Qu, who's also an adviser to China's National Health Commission weight management committee. Foreign medicines have long enjoyed higher trust and recognition in China, where the local biotech industry is still overcoming past quality issues. Skepticism about the quality of domestic generic medicines also remains high among Chinese – and rare backlash from doctors earlier this year fuelled questions about whether government efforts to slash treatment prices had come at the cost of efficacy. The relative price differences between foreign and domestic weight loss drugs could be much smaller than in PD-(L)1 medicines used to treat cancer, added Yang Huang, senior analyst for China healthcare research at JP Morgan. 'We think foreign companies could be more willing to lower prices for their weight loss drugs in China,' he said, 'as we have seen in the US market where major weight loss drug players have started engaging in price competition.' Going forward, 'you'll see a lot more competitors in the China market versus anywhere else,' said Justin Wang, head of LEK's China practice. 'It will be unlikely for one or two companies to dominate the whole market.' BLOOMBERG Join ST's Telegram channel and get the latest breaking news delivered to you.
AsiaOne
3 days ago
- AsiaOne
Eye care giant Alcon keeps 'lens' on the future with expanded manufacturing and logistics facility in Tuas, Singapore News
Eye care-device giant Alcon officially opened its expanded state-of-the art manufacturing and logistics facility in Tuas Biomedical Park on Friday (June 27) morning. This brings Alcon's investments in Singapore to more than US$600 million (S$765 million) since it began operations in Singapore back in 2005. The completed Tuas facility is one of the Swiss-American firm's largest high-tech manufacturing sites with Industry 4.0 capabilities, advanced automation and smart manufacturing systems to meet the increasing global demand for its contact lenses. Amid a growing middle class and rising demand for quality healthcare, the Asia-Pacific region continues to be the fastest-growing market for medical technology, with its market value projected to reach nearly S$300 billion by 2030. This puts the region second only to the US as a source of demand for medical technology (Medtech). "Singapore is home to some of the world's best-in-class Medtech manufacturing palnts. The sector has been growing steadily, with a manufacturing output of S$19.4 billion in 2023. This marks a $5.2 billion increase over the past decade," said Senior Minister of State for Trade and Industry Low Yen Ling at the opening ceremony of Alcon's expanded facility. Beyond strengthening innovation and supply chain resilience within Singapore's MedTech ecosystem, Alcon's investment is also expected to benefit Singaporean workers and small- and medium-sized enterprises (SMEs) in Singapore. Muhammad Haiqal Bin Sapuan, an associate supervisor at Alcon made the switch from the oil and gas industry, through the Career Conversion Programme (CCP), in 2022 to have more time with his family. A year and a half into his role as a senior technician, he was nominated by his peers to step up as an associate supervisor. [[nid:707984]] "That recognition gave me confidence. I started off as an interim, and it was tough at first, but the team's support made the difference," said Haiqal. To date, nearly 180 Singaporean workers have benefitted from the CCP to become Alcon associates. Alcon's new facility is expected to create new job opportunities in production operations, quality control and supply chain management. It is also expected to strengthen innovation and supply chain resilience within Singapore's Medtech ecosystem through initiatives such as the Partnership for Capability Transformation, which partners local SMEs to buiild capabilities from precision moulding to packaging, helping them to scale and compete globally. [[nid:715407]] editor@
Business Times
3 days ago
- Business Times
Swiss-American eye care firm Alcon launches expanded Tuas manufacturing facility
[SINGAPORE] Alcon, a Swiss-American pharmaceutical and medical device company specialising in eye care products, opened its expanded manufacturing and logistics facility in Tuas on Friday (Jun 27). This brings its total investment in Singapore to more than US$600 million since opening its first manufacturing site here in 2005. Located in Tuas Biomedical Park, the facility is one of Alcon's largest manufacturing sites, featuring advanced automation, smart manufacturing systems and industry 4.0 capabilities to support the increasing global demand for its contact lenses. It is also designed for operational efficiency and sustainability, with automation; digital systems; and features that reduce energy use, water consumption and waste. It has achieved zero waste to landfill and supports scalable production for global demand. Speaking at the launch event, Senior Minister of State for Trade and Industry Low Yen Ling said the partnership between Alcon and Singapore over the past 20 years exemplifies how deep, sustained collaboration can drive industrial growth and create meaningful careers for Singaporeans. 'Singapore is home to some of the world's best-in-class medtech manufacturing plants. The sector has been growing steadily, with a manufacturing output of S$19.4 billion in 2023, a nearly fourfold increase over the past decade,' she said. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up In a statement, Alcon said that the expansion is expected to create new 'high-value' jobs in areas such as manufacturing, quality control and distribution management. It will also support Singapore's ambition to grow its medtech workforce, which comprises over 400 companies and employs more than 16,000 people as of 2024. The company partners with local institutions and workforce programmes to build skills in precision engineering, biomedical sciences and artificial intelligence automation, supporting the growth of Singapore's medtech sector. One initiative is the Career Conversion Programme (CCP), which allowed the firm to tap into a broader, more diverse talent pool, including mid-career switchers and individuals seeking new roles. To date, nearly 180 associates have benefited. Muhammad Haiqal Sapuan, a beneficiary of the programme, worked in the oil and gas sector previously and joined Alcon as a senior technician in 2022. After participating in the CCP and undergoing strong mentoring, he now serves as an associate supervisor, leading a team of 15 in production technical operations. Alcon currently employs more than 25,000 people worldwide and serves over 260 million patients across 140 countries annually.
